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S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  How needle exchange is  organised is  cri tical  (2003). Findings  analys is  of seminal  and more recent studies  from s ix ci ties  which make the point that how needle
exchange is  organised is  cri tical  to i ts  success . See also other parts  of the same series  of reviews (2003 and 2004) on needle exchange and hepati tis  C.
K  Needle exchange coverage is  key (2007). Research in Cal i fornia  confi rms that l iberal  exchange pol icies  improve coverage which in turn reduces  vis i tors ’ ri sks  of
contracting or spreading blood-borne diseases.
K  Focus ing on syringe distribution rather than exchange cut HIV risk in Vancouver (2010). Among the pol icy changes  which seem to have led to a  step down in risk
behaviour and HIV incidence were removing the l imit on how many syringes  could be obtained, not requiring return of used equipment, and separating syringe
distribution from col lection of used equipment. For more on the dire s i tuation which prompted pol icy change, see (p. 3 of the PDF fi le, p. 26 of document) this
Findings  analys is .
K  Pol icies  stem from underlying vis ion of the purpose of needle exchange (2002). Canadian study discovered that exchanges  whose staff saw syringes  and needles
not as  the means to avoid infection, but primari ly as  pos ing a  risk to injectors  and to the publ ic, tended to counterproductively l imit the amount they gave out and
to ins ist on one-for-one exchange. For more on the study see (p. 2 of the PDF fi le, p. 26 of document) this  Findings  analys is .
K  Health promotion ethos  guides  Finnish exchanges  (Finnish National  Publ ic Health Insti tute and Department of Infectious  Disease Epidemiology and Control ,
2008). Finnish exchanges  are known as  health counsel l ing centres , symbol is ing that though needle exchange is  core, the aim is  a  comprehensive health care and
disease prevention service. The l inked evaluation thoughtful ly describes  the choices  and di lemmas in setting up and developing such a service as  they have played
out in practice in this  national  programme.
K  Bui ld on access  and trust to open doors  to other services  (2011). Feel ing safe and accepted meant users  of Canadian needle exchanges  were more l ikely to seek
and act on referral  to services  such as  counsel l ing, nurs ing, HIV, hepati tis  C and sexual  infection testing and information, welfare, financial  support, and housing
– important l i fe-improvers  for this  multiply disadvantaged population divorced from mainstream provis ion.
R  Organisational  pol icies  on equipment supply and anci l lary services  determine exchange effectiveness  (2004). Last of a  four-part Findings  series  on needle
exchange and hepati tis  C identi fies  the active ingredients  needed to maximise impact, including service pol icies .
R  Phi losophy should be that abundant supply is  good (2013). Extens ive UK review updated in 2013 which underpinned NICE guidance (see below) offers  support
for exchange programme pol icies  and phi losophies  which promote unrestricted and convenient supply of a  range of injecting equipment to maximal ly curb spread
of disease.
G  NICE says  abundance is  the objective for injecting equipment provis ion (NICE, 2014). UK’s  officia l  health advisory body says  exchange pol icies  should be to
supply customers  with as  much of the right kind of equipment as  they need and to a l low them to take equipment for others  – whi le at the same time promoting
moves away from injecting from drug use al together.
G  Scottish guidance on running and commiss ioning needle exchanges  (Scottish Government, 2010). Includes  needs assessment, locations, opening hours , s taff
training, injecting equipment provis ion pol icies , and integration with other services .
G  Guide to starting and managing needle and syringe programmes (World Health Organization [etc], 2007). Detai led manual  for service planners  and managers
including where and how services  should operate, types  of injecting equipment provided, services  other than this  provis ion, staffing, gaining community support,
and monitoring how wel l  you are doing.
G  Methadone as  recovery platform and harm reduction ([UK] National  Treatment Agency for Substance Misuse, 2012). UK cl inical  consensus  on methadone
maintenance and al l ied programmes tries  to balance harm reduction objectives  with a  commitment to long-term recovery.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and this  hot topic on hepati tis  C prevention.
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What is this cell about? As described more fully in the cell A1 bite, about reducing the harms experienced by the user as a result of their
drug use, without necessarily reducing use or seeking to overcome dependence. Common interventions include needle exchanges and
substituting a legally prescribed drug of the same type for the original (and usually illegally obtained) substance, also considered as a
treatment for addiction in row 3. This cell is however not about the content of the intervention (for which see cell A1), but about what
kinds of organisations are best placed to deliver these. Organisational ethos and objectives largely determine operational policies such
as methadone dosing and how many needles and syringes injectors are given by exchanges and on what terms. In turn these directly
affect the service’s potential harm reduction impact.
Where should I start? After reading these Findings case studies of how needle exchange has worked or not worked in six cities, no one
should remain under the illusion that it is enough just to open the doors and offer local injectors free sterile injecting equipment.
Planners should be intimately acquainted with the local context and gear the organisation accordingly – not just drug use patterns and
disease levels, but the psychological, social and material resources available to injectors to support healthier practices, alternative
sources of injecting equipment, and accessibility of other services like addiction treatment. Failure to take these into account could mean
the flow of equipment from the exchange simply feeds unchanged infection risk behaviour or replaces one source of sterile equipment
with another, creating no net benefit. Another important lesson is to find ways to work round local opposition to abundant equipment
supply rather than being forced to make restrictions so undermining that even in the presence of the exchange, HIV and hepatitis
infections soar. When that happens, chances are that needle exchange itself will be blamed for the failures, not the restrictions its
organisers were or felt forced to place on it – a pernicious kind of self-fulfilling prophecy.
Highlighted study With the escape route to pharmacy purchases cut off by the need for a prescription, California provided the context for
proving that exchange policies really do affect whether services meet NICE’s ideal of supplying their users with more than they need to
inject with a fresh set each time, and in turn the probability that they will avoid injecting practices which risk infection. Way out in front
were exchanges which simply provided as many needles and syringes as the injector needed regardless of how many they brought back.
Another important finding was that injectors in treatment were twice as likely to be adequately supplied as those who were not,
confirming that exchanges can make reaching this ideal easier for themselves by engaging customers in treatment. This probably reflects
a synergistic impact, with exchanges facilitating treatment entry and treatment stabilising lives and reducing injection frequency, making
it easier for exchanges to meet patients’ remaining needs for injecting equipment. That finding takes us into the territory explored below
of what harm reduction services are primarily there to promote.
Issues to think about
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 What is a harm reduction service for? Just one issue for you to ponder, but a (the?) big one, because surely the first thing any
organisation should be clear about, is what it is there to achieve. The answer seems self-evident – to reduce harm. But what counts as
harm, and whose harm? According to the UK Harm Reduction Alliance, harms may be to health or social or economic in nature, and may
affect individuals, communities, or whole societies. That opens the way to taking opposing stances in the name of harm reduction, from
prioritising the health of drug users to (if need be) sacrificing this to promote other social objectives and avoid costs. In the UK there are
indeed different interpretations of harm reduction, each seemingly ‘self-evident’ to their adherents. In 2012 the UK government’s
“roadmap” to a recovery-oriented treatment system subjugated “All our work on combating blood borne viruses” to the national
strategy’s “strategic recovery objective”, arguing that, “It is self-evident that the best protection against blood borne viruses is full
recovery”. What ‘full recovery’ entailed was never spelt out, but what it did not entail was clear; out of the mix was continuing drug use
of the kind which might prompt needle exchange attendance and remaining in opioid maintenance prescribing programmes.
For the UK Harm Reduction Alliance and partners including the UK Recovery Federation, all this was not all self-evident. Their response
transformed the government’s Putting full recovery first title in to Putting public health first, challenging the “ideologically-driven
hierarchy” which places full recovery at the top, with “any other achievement marked as inferior”. That theme was trenchantly taken up
by the Australian Injecting & Illicit Drug Users League. Concerned that the nation’s harm reduction orientation was under threat from UK-
style “new recovery”, they attacked the UK government’s roadmap, insisting “Harm Reduction is the goal – not a step along the ‘road to
recovery’ or the path to ‘freedom from dependence’.” This formulation echoed their core belief that harm reduction is the “principle
paradigm upon which drugs policy should be based. All other approaches (eg demand reduction, supply reduction) can have validity only
where there is strong evidence that they are appropriate, practical and equitable means of reducing drug-related harm.” In other words,
they reversed the primacy order so self-evident to the UK government, subjugating treatment and recovery to harm reduction, not the
other way round.
These polarities are endemic in debates about methadone maintenance and allied approaches for heroin addiction, seen as both
treatments for addiction and harm reduction while dependence continues. A recent UK attempt to reconcile these objectives complained
that “the protective benefits [ie, harm reduction] have too often become an end in themselves rather than providing a safe platform from
which users might progress towards further recovery”, and was prepared to see this progress pursued even if it “will sometimes lead to
people following a potentially more hazardous path, with the risk of relapse”. At the same time, “preservation of benefit” was seen as a
legitimate reason for continuing treatment; not least among those benefits is the preservation of life and health.
Having rehearsed the arguments, try asking yourself where you stand on these issues: Is harm reduction a primary goal, a second-best
outcome when recovery is for the moment unattainable, or ideally an engagement strategy and platform for recovery? When trying for
‘full recovery’ (entailing planned treatment exit and no illegal drug use or prescribed substitutes) risks reversing harm reduction gains, on
what basis can the decision be made about which takes priority? Should needle exchange staff actively pursue treatment entry and
recovery objectives for their clients, even if it risks some being deterred from using the exchange?
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